India is entering a major new phase in the semaglutide market. The country has seen strong interest from drug makers that want to produce lower-cost versions of this popular medicine for diabetes and weight management. Novo Nordisk’s Indian patent for semaglutide expired in March 2026. This has opened the door for more Indian companies to seek approvals and launch their own products.
Semaglutide is a GLP-1 medicine. It helps control blood sugar and can also support weight loss. It is available as an injection and as a tablet. Because it is a complex peptide drug, its quality depends on much more than the correct amount of active ingredient. The purity of the peptide, unwanted substances, sterility, stability and the quality of the final product all matter.
This makes manufacturing standards especially important as more Indian companies enter this market.
CDSCO has a key role
The Central Drugs Standard Control Organisation, or CDSCO, is the main national drug regulator in India. Its Subject Expert Committee, or SEC, reviews scientific and clinical information before it gives recommendations on new drug applications.
In 2026, CDSCO committees reviewed several semaglutide products. In March, the SEC accepted Phase III clinical trial data and recommended permission for the manufacture and marketing of semaglutide.
In May and June, the regulator also reviewed synthetic-origin semaglutide injections for manufacture and marketing. These decisions show that India is moving toward a larger domestic supply of semaglutide products.
The regulator has also reviewed semaglutide tablets. A January 2026 SEC document lists synthetic-origin semaglutide tablets at 3 mg, 7 mg and 14 mg.
Synthetic semaglutide is important
One major point in India’s semaglutide market is the use of synthetic-origin material. Semaglutide is a peptide, so its manufacture requires careful control of the chemical process and the final substance.
For an Indian manufacturer, the process must produce the same required molecular structure every time. The manufacturer must also control impurities that can arise from the raw materials, chemical steps and purification process.
The final active pharmaceutical ingredient, or API, must meet its approved specifications before it can move into the finished drug process. A manufacturer cannot rely only on a simple purity result. A strong quality system must show that the material has the correct identity, strength and purity and that unwanted substances remain within approved limits.
This becomes even more important when production moves from a small development batch to a commercial scale.
Manufacturing needs strict quality control
Semaglutide manufacture needs a controlled pharmaceutical environment. The facility must have suitable equipment, trained staff, written procedures and a quality system that can detect problems before they affect patients.
Raw materials need proper checks before use. The manufacturing process needs defined controls and records. Equipment must be clean and suitable for its purpose. Critical steps need validation or other documented evidence that they work in a reliable way.
The same principle applies to the testing laboratory. Analytical methods must be suitable for the product and properly validated. Results must be traceable, and laboratories need systems for handling deviations, out-of-specification results and changes to approved methods.
India has also increased its focus on pharmaceutical manufacturing quality. In July 2026, the drug regulator said more than 960 risk-based inspections and audits had taken place since late 2022, with about 860 sites facing some form of enforcement action. The regulator also said manufacturers had to align with World Health Organization quality standards.
This wider quality drive is important for semaglutide because the product is expected to reach a large number of patients.
Testing of the semaglutide API
Testing starts with the API. The laboratory must confirm that the material is actually semaglutide and that it meets the approved quality requirements.
An assay test checks the amount of semaglutide present. Identity tests confirm the substance. Purity tests look for unwanted compounds and related substances.
Peptide drugs also need careful control of related impurities. These may arise from incomplete reactions, unwanted peptide forms or breakdown during storage. The exact tests and limits must come from the approved product specification and the relevant regulatory dossier.
Other tests can apply based on the manufacturing process and the form of the API. These can include water content, residual solvents and other process-related impurities.
A manufacturer should not simply copy a test from another semaglutide product and assume that it is suitable. The method must be shown to work for the specific material and product.
Testing of semaglutide injections
Injectable semaglutide has additional requirements because the product goes directly into the body. Sterility is therefore a major concern.
The finished injection needs suitable tests for sterility and bacterial endotoxins. It may also require checks for visible and sub-visible particles, appearance, pH, strength and other product-specific characteristics.
The container and closure system also matter. A pre-filled pen or other delivery system must protect the medicine throughout its shelf life. The manufacturer must show that the product remains within its approved quality limits under the proposed storage conditions.
Stability studies are another important part of the process. These studies help establish the shelf life and storage conditions. The company must show that the product remains safe, effective and within its quality specifications over time.
Tablets need a different approach
Oral semaglutide tablets have their own quality concerns. The tablet must contain the correct amount of active substance and release it in a controlled and consistent way.
Manufacturers must check factors such as assay, related substances, dissolution and physical properties. The exact test package depends on the formulation and approved specifications.
CDSCO’s review of oral semaglutide shows that regulatory approval can also depend on clinical evidence. For some applications, the regulator may ask for additional verification of Phase III trial data before it considers marketing permission.
This shows that manufacturing quality alone is not enough. A company also needs strong evidence of safety, quality and effectiveness.
Scale-up is a major challenge
One of the biggest risks for Indian manufacturers is the move from laboratory or pilot production to commercial production.
A process may work well at a small scale but behave differently at a much larger scale. Mixing, purification, temperature control and other process conditions can change. Even small changes can affect peptide quality.
Recent events show why this issue deserves attention. In July 2026, Dr. Reddy’s Laboratories said it had stopped production of new semaglutide batches after an impurity issue with the API. Torrent Pharmaceuticals also recalled selected batches of its semaglutide pens after a notice from its manufacturer.
These events underline a simple point: fast market growth cannot replace strong quality control.
India needs reliable testing standards
India’s semaglutide market will need clear and reliable specifications for both API and finished products. Companies will need validated analytical methods, qualified laboratories and strong documentation.
International standards can also matter for companies that plan to export. A product made for India may later need to meet requirements from regulators in other markets. That can require additional analytical data, stability work and manufacturing controls.
The Indian regulatory system will therefore remain important as companies move from approval to large-scale supply.
Quality will decide the next stage
India has a strong pharmaceutical manufacturing base, and semaglutide offers a major commercial opportunity. The expiry of the Indian patent has created space for local companies, while CDSCO reviews show that several products are moving through the regulatory system.
But semaglutide is not a simple conventional tablet. It is a peptide medicine with demanding quality requirements. Manufacturers must control the API, impurities, formulation, sterility where applicable, stability and the final delivery system.
The recent impurity-related supply problems also show how important these controls are.
For India, the next step is not only to produce more semaglutide. It is to produce it with consistent quality, reliable testing and strong regulatory control. If manufacturers can maintain those standards at commercial scale, India could become an important source of affordable semaglutide for both domestic patients and global markets.
ALSO READ: Indian Rupee Opens Stronger at 95.64 Against US Dollar
